Events

The call featured a presentation by Key Opinion Leaders:

• Peter Trainer, MD (Crinetics VP of Clinical Endocrinology)
• Monica Roberto Gadelha, MD (Medical School of the Universidade Federal do Rio de Janeiro)

These experts discussed the current treatment landscape, which is comprised primarily of injected somatostatin receptor ligand (SRL) depots, and the unmet medical need in treating patients with acromegaly. They also shared their thoughts and discuss the implications from the Phase 2 ACROBAT Edge and Evolve studies with oral paltusotine, a novel, oral, selective, nonpeptide, somatostatin receptor type 2 biased agonist designed for the treatment of acromegaly.

Based on positive Phase 2 ACROBAT results, which were released on October 26, 2020, Crinetics expects to begin its Phase 3 program in the first half of 2021 to further characterize the differentiating features relative to the current standard of care.

In addition to discussing oral paltusotine, Crinetics’ management team provided a brief update on two other pipeline assets that will begin Phase 1 trials in the coming months.

To view webcast archive

Crinetics-Paltusotine-Acromegaly-KOL-Event-Presentation